<DOC>
	<DOCNO>NCT00791427</DOCNO>
	<brief_summary>This open-label study assess electrophysiologic test retina Electoretinogram ( ERG ) /Electrooculogram ( EOG ) test patient exudative age-related macular degeneration ( AMD ) . The standard FDA-approved treatment wet AMD ranibizumab ( Lucentis ) . This study focus ERG EOG test evaluate retinal response ranibizumab treatment AMD .</brief_summary>
	<brief_title>ERG/EOG Study AMD Patients Treated With Ranibizumab</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Age &gt; 55 year Patients include study must AMD choroidal neovascularization BCVA 20/20 20/400 Lesion size le equal 12 MPS disc area Prior treatment antiVEGF agent within 6 month enrollment study Pregnancy ( positive pregnancy test ) Premenopausal woman use adequate contraception . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , IUD , contraceptive hormone implant patch Prior enrollment study Any condition investigator believe would pose significant hazard subject investigational therapy initiate Participation another simultaneous medical investigation trial Media insufficient obtain view Other cause CNV relate AMD Active ocular periocular infection Ocular surgery within 1 month prior study</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>